[Federal Register Volume 86, Number 119 (Thursday, June 24, 2021)]
[Notices]
[Page 33359]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-13249]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-858]


Bulk Manufacturer of Controlled Substances Application: Bulk 
Manufacturer of Marihuana: Annac Medical Center LC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is providing notice 
of an application it has received from an entity applying to be 
registered to manufacture in bulk basic class(es) of controlled 
substances listed in schedule I. DEA intends to evaluate this and other 
pending applications according to its regulations governing the program 
of growing marihuana for scientific and medical research under DEA 
registration.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefor, may file written comments on or objections to 
the issuance of the proposed registration on or before August 23, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW 8701 
Morrissette Drive, Springfield, Virginia 22152. To ensure proper 
handling of comments, please reference Docket No--DEA-858 in all 
correspondence, including attachments.

SUPPLEMENTARY INFORMATION: The Controlled Substances Act (CSA) 
prohibits the cultivation and distribution of marihuana except by 
persons who are registered under the CSA to do so for lawful purposes. 
In accordance with the purposes specified in 21 CFR 1301.33(a), DEA is 
providing notice that the entity identified below has applied for 
registration as a bulk manufacturer of schedule I controlled 
substances. In response, registered bulk manufacturers of the affected 
basic class(es), and applicants therefor, may file written comments on 
or objections of the requested registration, as provided in this 
notice. This notice does not constitute any evaluation or determination 
of the merits of the application submitted.
    The applicant plans to manufacture bulk active pharmaceutical 
ingredients (APIs) for product development and distribution to DEA 
registered researchers. If the application for registration is granted, 
the registrant would not be authorized to conduct other activity under 
this registration aside from those coincident activities specifically 
authorized by DEA regulations. DEA will evaluate the application for 
registration as a bulk manufacturer for compliance with all applicable 
laws, treaties, and regulations and to ensure adequate safeguards 
against diversion are in place.
    As this applicant has applied to become registered as a bulk 
manufacturer of marihuana, the application will be evaluated under the 
criteria of 21 U.S.C. 823(a). In addition to seeking to produce 
marihuana extract, this applicant is separately seeking to cultivate 
marihuana. See Notice of Application, Bulk Manufacturers of Marihuana, 
84 FR 44920, 44922 (Aug. 27, 2019). DEA will conduct this evaluation in 
the manner described in the rule published at 85 FR 82333 on December 
18, 2020, and reflected in DEA regulations at 21 CFR part 1318.
    In accordance with 21 CFR 1301.33(a), DEA is providing notice that 
on April 14, 2021, Annac Medical Center, LC, 5172 West Patrick Lane, 
Suite 100, Las Vegas, Nevada 89117-8911, applied to be registered as a 
bulk manufacturer of the following basic class(es) of controlled 
substances:

------------------------------------------------------------------------
                                                       Drug
                Controlled substance                   code    Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols...............................    7370          I
------------------------------------------------------------------------


William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-13249 Filed 6-23-21; 8:45 am]
BILLING CODE P